• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cereno Scientific

4.62 SEK

+4.86 %

Less than 1K followers

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.86 %
-16.83 %
-23.00 %
-33.96 %
-44.62 %
-57.02 %
+901.30 %
+32.26 %
-23.21 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Read more
Market cap
1.44B SEK
Turnover
4.4M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17/6
2026

General meeting '26

26/8
2026

Interim report Q2'26

4/11
2026

Interim report Q3'26

Press release6/3/2026, 5:45 AM

Cereno Scientific to present at BIO International Convention 2026 and advance global partnering discussions

Cereno Scientific
Press release6/3/2026, 5:45 AM

Cereno Scientific presenterar vid BIO International Convention 2026 och deltar i globala partneringdiskussioner

Cereno Scientific
Third party research5/27/2026, 6:49 AM

Cereno Scientific: Preclinical development for CS585 - Edison

Cereno Scientific has announced that its third asset, CS585 (a potent and selective agonist of the prostacyclin receptor), will be tested in preclinical disease model studies relating to antiphospholipid syndrome (APS), a rare autoimmune disease associated...

Cereno Scientific

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/27/2026, 6:00 AM

Cereno Scientific Publishes Interim Report for Q1 2026

Cereno Scientific
Regulatory press release5/27/2026, 6:00 AM

Cereno Scientific publicerar delårsrapport för första kvartal 2026

Cereno Scientific
Press release5/26/2026, 5:45 AM

Cereno Scientific Confirms First Volunteer Dosed in CS014 PK-bridging Study Supporting Phase II Development in PH-ILD

Cereno Scientific
Press release5/26/2026, 5:45 AM

Cereno Scientific bekräftar att första frivilliga deltagaren doserats i PK bridging-studien med CS014 som stödjer Fas II-utveckling inom PH-ILD

Cereno Scientific
Regulatory press release5/22/2026, 5:24 PM

Cereno Scientific publishes Annual Report for 2025

Cereno Scientific
Regulatory press release5/22/2026, 5:24 PM

Cereno Scientific publicerar årsredovisning för 2025

Cereno Scientific
Press release5/21/2026, 5:45 AM

Cereno Scientific to Initiate Preclinical Evaluation of CS585 in Rare Disease Antiphospholipid Syndrome (APS) Progressing toward Clinical Phase

Cereno Scientific
Press release5/21/2026, 5:45 AM

Cereno Scientific initierar preklinisk utvärdering av CS585 i den sällsynta sjukdomen antifosfolipidsyndrom (APS) med framfart mot klinisk fas

Cereno Scientific
Regulatory press release5/15/2026, 12:30 PM

Cereno Scientific give notice to attend the Annual General Meeting 2026

Cereno Scientific
Regulatory press release5/15/2026, 12:30 PM

Cereno Scientific kallar till årsstämma 2026

Cereno Scientific
Press release5/11/2026, 5:30 AM

Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension

Cereno Scientific
Press release5/11/2026, 5:30 AM

Cereno Scientific ingår samarbete med PHA Europe & Global för att främja patientcentrerad läkemedelsutveckling inom pulmonell hypertension

Cereno Scientific
Press release4/10/2026, 6:45 AM

Cereno Scientific deltar vid Nordic Health Summit Japan och ChinaBio Partnering Forum 2026

Cereno Scientific
Press release4/10/2026, 6:45 AM

Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026

Cereno Scientific
Press release4/4/2026, 6:00 AM

Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH

Cereno Scientific
Press release4/4/2026, 6:00 AM

Cereno Scientific lyfter det strategiska värdet av att ha uppnått primär endpoint avseende säkerhet och tolerabilitet i 12-månadersdata för CS1 vid PAH

Cereno Scientific
Regulatory press release3/31/2026, 5:30 AM

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program

Cereno Scientific